Lori Stockert

Anti‐IL21 receptor monoclonal antibody (ATR‐107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: A phase I, first‐in‐human study

Fei Hua, Gail M. Comer, Lori Stockert et al. · The Journal of Clinical Pharmacology · 2013 · 53 citations

Clinical Immunology, Healthy Subjects, Immunotoxicology +19

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure

Gerd R Burmester, Peter Nash, Bruce E. Sands et al. · RMD Open · 2021 · 49 citations · Full text

Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial

Stanley Cohen, Janet Pope, Boulos Haraoui et al. · The Lancet Rheumatology · 2019 · 37 citations · Full text

Rheumatoid Disorder, Rheumatology, Low Disease Activity +8

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis

Jon T. Giles, Alexis Ogdie, Juan J. Gómez‐Reino et al. · RMD Open · 2021 · 37 citations · Full text

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies

Ara Dikranian, Miguel Á. González‐Gay, Frank R. Wellborne et al. · RMD Open · 2022 · 29 citations · Full text